Uric acid as a potential mediator of cardiovascular morbidity in obstructive sleep apnea syndrome [2]

dc.authorid0000-0002-4717-3000
dc.contributor.authorKanbay, Asiye
dc.contributor.authorInonu, Handan
dc.contributor.authorSolak, Yalcin
dc.contributor.authorErden, Abdulsamet
dc.contributor.authorUslu, Emine
dc.contributor.authorYuksel, Sevgi Arik
dc.contributor.authorOzturk, Mehmet Akif
dc.date.accessioned2025-05-10T19:49:12Z
dc.date.issued2014
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstractBackground and aims: Obstructive sleep apnea (OSA) is now considered as an independent risk factor for cardiovascular (CV) disease. Although uric acid is increasingly being implicated in CV morbidity and mortality, no study attempted to determine independent role of uric acid in CV morbidity of OSA patients. We aimed to assess the role of serum uric acid as a potential mechanism of CV morbidity in a nonselected cohort of OSA patients. Methods: This was a cohort study in which patients who had undergone a formal sleep study for diagnosis of OSA were recruited. Included patients were grouped according to apnea-hypopnea index (AHI) as mild, moderate and severe OSA. Patients with AHI < 5 served as control group. Patients were interrogated as to cardiovascular morbid conditions which included prior history and an established diagnosis of coronary artery disease, cerebrovascular accident, congestive heart failure due to coronary artery disease and arrhythmias. Results: 436 OSA patients included (72 controls, 97 with mild, 75 with moderate, and 192 with severe OSA). The severe group also had higher serum uric acid level compared with the control and other OSA groups. Linear regression showed that the Ln uric acid was positively associated with Ln AHI score. In unadjusted logistic regression, severe OSA was associated with higher odds of a cardiovascular event, OR = 2.81 (1.307-6.041), p = 0.0081 while the other categories of sleep apnea were not. However, severe OSA was no longer significant after adjusting for age, gender, diabetes mellitus status, hypertension status, BMI, and smoking, OR = 1.882 (0.826-4.287), p = 0.1322. Uric acid was significantly higher in those who had a cardiovascular event even in the mild, moderate and severe OSA groups. Conclusion: Hyperuricemia is strongly associated with cardiovascular disease in OSA patients. This strong relationship persists even after controlling for well-known traditional risk factors for cardiovascular disease. (C) 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
dc.description.sponsorshipNIH [T32DK7135, DK80764, PO1fA1045897, HL113809]; Dept of Defense, State of Colorado, Danone, Amway and Questcor [PR130106]
dc.description.sponsorshipDr Johnson is an inventor on patent applications and a patent related to lowering uric acid to reduce blood pressure, insulin resistance and renal disease, and is a Founder in XORT Therapeutics. He currently has grants from the NIH (T32DK7135, DK80764, PO1fA1045897, HL113809) and the Dept of Defense (PR130106), State of Colorado, Danone, Amway and Questcor; he has two lay books (The Sugar Fix (Rodale 2008) and The Fat Switch (Mercola.com)) and he is on the Scientific Board of Amway. All other authors declare there are no conflicts of interest between authors.
dc.identifier.doi10.1016/j.ejim.2014.04.005
dc.identifier.endpage476
dc.identifier.issn0953-6205
dc.identifier.issn1879-0828
dc.identifier.issue5
dc.identifier.pmid24793835
dc.identifier.scopus2-s2.0-84901588642
dc.identifier.scopusqualityQ1
dc.identifier.startpage471
dc.identifier.urihttps://doi.org/10.1016/j.ejim.2014.04.005
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11960
dc.identifier.volume25
dc.identifier.wosWOS:000336483000019
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofEuropean Journal of Internal Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.subjectUric acid
dc.subjectObstructive sleep apnea
dc.subjectCardiovascular disease
dc.subjectCardiovascular risk factor
dc.titleUric acid as a potential mediator of cardiovascular morbidity in obstructive sleep apnea syndrome [2]
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
11960.pdf
Boyut:
592.53 KB
Biçim:
Adobe Portable Document Format